www.cygenia.com
Epigenetics is a new area of research that opens great potential for comprehensive cellular analysis. Cygenia GmbH has established methods for various epigenetic biomarkers which are continuously further developed. One line of research is further optimization of our Epigenetic-Aging-Signature: The results are indicative for biological age and for life expectancy. We described a method based on DNA methylation levels at three specific CpGs (Weidner CI et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biology, 2014; 15:R24.; Lin Q, et al. DNA methylation levels at individual age-associated CpG sites can be indicative for life expectancy. Aging 2016; 8: 394-401). This method is concurrently further optimized (including analysis of buccal swab samples; Eipel M et al., AGING US, accepted for publication.
The company was founded in March 2014. It is the first company to provide this kind of service on epigenetic biomarkers. Several of the assays have been designed at RWTH Aachen University Medical School in Aachen, Germany (patents pending). Cygenia addresses particularly scientists and clinicians. The results are provided in a ready-to-publish format. Cygenia GmbH is also very open to all kinds of scientific cooperation on these assays or beyond.